Assessment of Imaging Findings of Renal Carcinoma Subtypes with 3.0T MRI.
Journal
Nigerian journal of clinical practice
ISSN: 1119-3077
Titre abrégé: Niger J Clin Pract
Pays: India
ID NLM: 101150032
Informations de publication
Date de publication:
01 Nov 2023
01 Nov 2023
Historique:
received:
16
05
2023
accepted:
06
07
2023
medline:
5
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
ppublish
Résumé
The prevalence of renal masses has escalated as a result of the augmented utilization of cross-sectional imaging techniques. The approach to managing renal masses may exhibit variability contingent upon the subtype of renal cell carcinoma (RCC). This research aimed to distinguish between clear cell and papillary RCCs, utilizing dynamic contrast magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI). The study assessed the MR images of 112 patients with RCC. Two radiologists independently analyzed tumor size, vascular involvement, signal characteristics in T1- and T2-weighted sequences, the presence of hemosiderin, both microscopic and macroscopic fat content, enhancement patterns, and apparent diffusion coefficient (ADC) values derived from b-values of 1000 s/mm². Seventy patients had clear cell RCC, and 42 had papillary. In the clear cell RCC, microscopic fat content was significantly higher than the papillary RCC (P < 0.001). However, in papillary RCC, hemosiderin content was substantially greater (P = 0.001). On T2-weighted MR images, clear cell RCCs were usually hyperintense, while papillary RCCs were hypointense (P < 0.001). Even though the rapid enhancement pattern was observed in clear cell RCCs, the progressive enhancement pattern was more prevalent in papillary RCCs (P < 0.001). Hyperintensity on T2-weighted images, microscopic fat content, and rapid enhancement pattern may be indicative of clear cell RCC, whereas hypointensity on T2-weighted images, hemosiderin content, and a progressive contrast pattern may be diagnostic for papillary RCC.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of renal masses has escalated as a result of the augmented utilization of cross-sectional imaging techniques. The approach to managing renal masses may exhibit variability contingent upon the subtype of renal cell carcinoma (RCC).
AIM
OBJECTIVE
This research aimed to distinguish between clear cell and papillary RCCs, utilizing dynamic contrast magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI).
MATERIALS AND METHODS
METHODS
The study assessed the MR images of 112 patients with RCC. Two radiologists independently analyzed tumor size, vascular involvement, signal characteristics in T1- and T2-weighted sequences, the presence of hemosiderin, both microscopic and macroscopic fat content, enhancement patterns, and apparent diffusion coefficient (ADC) values derived from b-values of 1000 s/mm².
RESULTS
RESULTS
Seventy patients had clear cell RCC, and 42 had papillary. In the clear cell RCC, microscopic fat content was significantly higher than the papillary RCC (P < 0.001). However, in papillary RCC, hemosiderin content was substantially greater (P = 0.001). On T2-weighted MR images, clear cell RCCs were usually hyperintense, while papillary RCCs were hypointense (P < 0.001). Even though the rapid enhancement pattern was observed in clear cell RCCs, the progressive enhancement pattern was more prevalent in papillary RCCs (P < 0.001).
CONCLUSION
CONCLUSIONS
Hyperintensity on T2-weighted images, microscopic fat content, and rapid enhancement pattern may be indicative of clear cell RCC, whereas hypointensity on T2-weighted images, hemosiderin content, and a progressive contrast pattern may be diagnostic for papillary RCC.
Identifiants
pubmed: 38044783
doi: 10.4103/njcp.njcp_373_23
pii: 01253091-202311000-00025
doi:
Substances chimiques
Hemosiderin
9011-92-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1750-1757Informations de copyright
Copyright © 2023 Copyright: © 2023 Nigerian Journal of Clinical Practice.
Références
Laguna MP, Algaba F, Cadeddu J, Clayman R, Gill I, Gueglio G, et al. Current patterns of presentation and treatment of renal masses:A clinical research office of the endourological society prospective study. J Endourol 2014;28:861–70.
Wang W, Cao K, Jin S, Zhu X, Ding J, Peng W. Differentiation of renal cell carcinoma subtypes through MRI-based radiomics analysis. Eur Radiol 2020;30:5738–47.
Bahadoram S, Davoodi M, Hassanzadeh S, Bahadoram M, Barahman M, Mafakher L. Renal cell carcinoma:An overview of the epidemiology, diagnosis, and treatment. G Ital Nefrol 2022;39:2022–l3.
Truong LD, Shen SS. Immunohistochemical diagnosis of renal neoplasms. Arch Pathol Lab Med 2011;135:92–109.
Bhandari A, Ibrahim M, Sharma C, Liong R, Gustafson S, Prior M. CT-based radiomics for differentiating renal tumours:A systematic review. Abdom Radiol (NY) 2021;46:2052–63.
Ramamurthy NK, Moosavi B, McInnes MD, Flood TA, Schieda N. Multiparametric MRI of solid renal masses:Pearls and pitfalls. Clin Radiol 2015;70:304–16.
Choi YA, Kim CK, Park SY, Cho SW, Park BK. Subtype differentiation of renal cell carcinoma using diffusion-weighted and blood oxygenation level-dependent MRI. AJR Am J Roentgenol 2014;203:W78–84.
Gurel S, Narra V, Elsayes KM, Siegel CL, Chen ZE, Brown JJ. Subtypes of renal cell carcinoma:MRI and pathological features. Diagn Interv Radiol 2013;19:304–11.
Hötker AM, Karlo CA, Zheng J, Moskowitz CS, Russo P, Hricak H, et al. Clear cell renal cell carcinoma:Associations between CT features and patient survival. AJR Am J Roentgenol 2016;206:1023–30.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN):A multicentre, open-label, randomised phase 2 trial. Lancet Oncol 2016;17:378–88.
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 2017;71:426–36.
Capitanio U, Larcher A, Fallara G, Trevisani F, Porrini E, Di Marco F, et al. Parenchymal biopsy in the management of patients with renal cancer. World J Urol 2021;39:2961–8.
Schieda N, Davenport MS, Pedrosa I, Shinagare A, Chandarana H, Curci N, et al. Renal and adrenal masses containing fat at MRI:Proposed nomenclature by the society of abdominal radiology disease-focused panel on renal cell carcinoma. J Magn Reson Imaging 2019;49:917–26.
Childs DD, Clingan MJ, Zagoria RJ, Sirintrapun J, Tangtiang K, Anderson A, et al. In-phase signal intensity loss in solid renal masses on dual-echo gradient-echo MRI:Association with malignancy and pathologic classification. AJR Am J Roentgenol 2014;203:W421–8.
Muglia VF, Prando A. Renal cell carcinoma:Histological classification and correlation with imaging findings. Radiol Bras 2015;48:166–74.
Hötker AM, Mazaheri Y, Wibmer A, Karlo CA, Zheng J, Moskowitz CS, et al. Differentiation of clear cell renal cell carcinoma from other renal cortical tumors by use of a quantitative multiparametric MRI approach. AJR Am J Roentgenol 2017;208:W85–91.
Pedrosa I, Sun MR, Spencer M, Genega EM, Olumi AF, Dewolf WC, et al. MR imaging of renal masses:Correlation with findings at surgery and pathologic analysis. Radiographics 2008;28:985–1003.
Karlo CA, Donati OF, Burger IA, Zheng J, Moskowitz CS, Hricak H, et al. MR imaging of renal cortical tumours:Qualitative and quantitative chemical shift imaging parameters. Eur Radiol 2013;23:1738–44.
Bissada NK, Yakout HH, Babanouri A, Elsalamony T, Fahmy W, Gunham M, et al. Long-term experience with management of renal cell carcinoma involving the inferior vena cava. Urology 2003;61:89–92.
Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, Cortez AD, et al. Common and uncommon histologic subtypes of renal cell carcinoma:Imaging spectrum with pathologic correlation. Radiographics 2006;26:1795–806.
Cornelis F, Tricaud E, Lasserre AS, Petitpierre F, Bernhard JC, Le Bras Y, et al. Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. Eur Radiol 2014;24:1068–80.
Rosenkrantz AB, Sekhar A, Genega EM, Melamed J, Babb JS, Patel AD, et al. Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma. Eur Radiol 2013;23:579–87.
Campbell N, Rosenkrantz AB, Pedrosa I. MRI phenotype in renal cancer:Is it clinically relevant?. Top Magn Reson Imaging 2014;23:95–115.
Chandarana H, Rosenkrantz AB, Mussi TC, Kim S, Ahmad AA, Raj SD, et al. Histogram analysis of whole-lesion enhancement in differentiating clear cell from papillary subtype of renal cell cancer. Radiology 2012;265:790–8.
Sun MR, Ngo L, Genega EM, Atkins MB, Finn ME, Rofsky NM, et al. Renal cell carcinoma:Dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology 2009;250:793–802.
Serter A, Onur MR, Coban G, Yildiz P, Armagan A, Kocakoc E. The role of diffusion-weighted MRI and contrast-enhanced MRI for differentiation between solid renal masses and renal cell carcinoma subtypes. Abdom Radiol (NY) 2021;46:1041–52.
Outwater EK, Bhatia M, Siegelman ES, Burke MA, Mitchell DG. Lipid in renal clear cell carcinoma:Detection on opposed-phase gradient-echo MR images. Radiology 1997;205:103–7.
Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radiol 2016;8:484–500.
Chen Y, Wu N, Xue T, Hao Y, Dai J. Comparison of contrast-enhanced sonography with MRI in the diagnosis of complex cystic renal masses. J Clin Ultrasound 2015;43:203–09.
Mühlfeld AS, Lange C, Kroll G, Floege J, Krombach GA, Kuhl C, et al. Pilot study of non-contrast-enhanced MRI vs. ultrasound in renal transplant recipients with acquired cystic kidney disease:A prospective intra-individual comparison. Clin Transplant 2013;27:E694–701.
Li X, Xiang X, Lin HT. Differential diagnostic value of magnetic resonance diffusion-weighted imaging and apparent diffusion coefficient for renal clear cell carcinoma and non-clear cell carcinoma. Oncol Lett 2023;25:60.